Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome
Hematol Oncol
.
2022 Apr;40(2):302-306.
doi: 10.1002/hon.2950.
Epub 2021 Dec 3.
Authors
Hanyin Wang
1
,
Shulan Tian
2
,
Qing Zhao
3
,
Wendy Blumenschein
4
,
Jennifer H Yearley
4
,
Charla R Secreto
5
,
Sutapa Sinha
5
,
Timothy G Call
5
,
Yucai Wang
5
,
Sameer A Parikh
5
,
Saad S Kenderian
5
,
Rong He
6
,
Jose F Leis
7
,
Min Shi
6
,
Daniel L Van Dyke
6
,
Neil E Kay
5
,
Susan L Slager
2
,
Esteban Braggio
7
,
Huihuang Yan
2
,
Wei Ding
5
Affiliations
1
Department of Hospital Internal Medicine, Mayo Clinic Health System, Mankato, Minnesota, USA.
2
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
3
Biostatistics and Research Decision Sciences, Merck & Co., Inc., Kenilworth, New Jersey, USA.
4
Genome and Biomarker Sciences, Merck & Co., Inc., Kenilworth, New Jersey, USA.
5
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
6
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
7
Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA.
PMID:
34806797
DOI:
10.1002/hon.2950
No abstract available
Publication types
Letter
Comment
MeSH terms
Adenine / analogs & derivatives
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
Piperidines
Transcriptome*
Substances
Piperidines
ibrutinib
Adenine
Grants and funding
Merck & Co., Inc.